Please Wait
Applying Filters...

Annual Sales of 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17alpha) reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 7,465Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Lo Loestrin

02 3Myfembree/Ryeqo

PharmaCompass

07

Brand Name : Myfembree/Ryeqo

Norethisterone Acetate

arrow
AAPS 2024
Not Confirmed

Brand Name : Myfembree/Ryeqo

arrow
AAPS 2024
Not Confirmed

Norethisterone Acetate

Main Therapeutic Indication : Women's Healthcare

Currency : USD

2021 Revenue in Millions : 8

2020 Revenue in Millions : 0

Growth (%) : New Launch in 2021

blank

08

Brand Name : Myfembree/Ryeqo

Norethisterone Acetate

arrow
AAPS 2024
Not Confirmed

Brand Name : Myfembree/Ryeqo

arrow
AAPS 2024
Not Confirmed

Norethisterone Acetate

Main Therapeutic Indication : Women's Health

Currency : USD

2022 Revenue in Millions : 25

2021 Revenue in Millions : 8

Growth (%) : 234

blank

09

Brand Name : Myfembree/Ryeqo

Norethisterone Acetate

arrow
AAPS 2024
Not Confirmed

Brand Name : Myfembree/Ryeqo

arrow
AAPS 2024
Not Confirmed

Norethisterone Acetate

Main Therapeutic Indication : Women's Health

Currency : USD

2023 Revenue in Millions : 60

2022 Revenue in Millions : 32

Growth (%) : 110

blank